13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
17 檔
26.4%
According to the latest 13F quarterly dataset, Caligan Partners LP managed an equity portfolio of $2.1B at the end of Q3 2025, spanning 17 distinct U.S. exchange-listed positions.
In Q3 2025, Caligan Partners LP displayed an active expansion posture, initiating 7 new positions and adding to 7 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 24.18% | +10.06% | — | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 16.14% | -1.06% | -13.29% | |
| 3 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 13.77% | -5.00% | EXIT | |
| 4 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 11.07% | -0.04% | +96.61% | |
| 5 | EXEL | Exelixis Inc | Stock-Healthcare | 8.25% | -0.45% | — | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.51% | +7.32% | +67.12% | |
| 7 | ADMA | Adma Biologics Inc | Stock-Healthcare | 5.06% | -0.66% | — | |
| 8 | EOLS | Evolus Inc | Stock-Other | 3.33% | — | +23.85% | |
| 9 | ✓ | Merus N V | Stock-Other | 2.68% | — | -66.98% | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.34% | -2.86% | — | |
| 11 | ANIK | Anika Therapeutics Inc | Stock-Other | 1.77% | -0.39% | — | |
| 12 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.39% | +1.13% | — | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 1.28% | -2.04% | +266.85% | |
| 14 | INBX | Inhibrx Biosciences Inc | Stock-Other | 1.04% | — | — | |
| 15 | VRCA | Verrica Pharmaceuticals Inc | Stock-Other | 0.52% | -0.06% | — | |
| 16 | SLS | Sellas Life Sciences Group I | Stock-Other | 0.48% | — | — | |
| 17 | AURA | Aura Biosciences Inc | Stock-Other | 0.18% | +1.34% | +13.59% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +14.5% | -13.29% | Add |
| 2 | AGIO | Agios Pharmaceuticals Inc | +6.8% | +96.61% | Add |
| 3 | MLYS | Mineralys Therapeutics Inc | +6.7% | +37.44% | Add |
| 4 | RVMD | Revolution Medicines Inc | +3.1% | +67.12% | Add |
| 5 | TYRA | Tyra Biosciences Inc | +1.2% | +266.85% | Add |
| 6 | ✓ | Merus N V | -0.6% | -66.98% | Trim |
| 7 | LQDA | Liquidia CORP | -0.8% | — | Add |
| 8 | ANIK | Anika Therapeutics Inc | -2.7% | — | Unchanged |
| 9 | EXEL | Exelixis Inc | -3.5% | — | Unchanged |
| 10 | EOLS | Evolus Inc | -3.5% | +23.85% | Add |
| 11 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 12 | ADMA | Adma Biologics Inc | — | NEW | New buy |
| 13 | SG7 | Sage Therapeutics Inc | — | EXIT | Sold out |
| 14 | BCRX | Biocryst Pharmaceuticals Inc | — | EXIT | Sold out |
| 15 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 16 | AVTX | Avalo Therapeutics Inc | — | NEW | New buy |
| 17 | YMABUSD | Y-mabs Therapeutics Inc | — | EXIT | Sold out |
| 18 | INBX | Inhibrx Biosciences Inc | — | NEW | New buy |
| 19 | VRCA | Verrica Pharmaceuticals Inc | — | NEW | New buy |
| 20 | ✓ | Verrica Pharmaceuticals Inc | — | EXIT | Sold out |
| 21 | SLS | Sellas Life Sciences Group I | — | NEW | New buy |
| 22 | AURA | Aura Biosciences Inc | — | NEW | New buy |
| 23 | RZLT | Rezolute Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 17 disclosed positions in Q3 2025.
During Q3 2025, Caligan Partners LP's top holdings by market value included LQDA (24.2%)、ABVX (16.1%)、MLYS (13.8%). The largest single position, LQDA, represented 24.2% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, ABVX, MLYS) accounted for 26.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
ADMA
市值: $38.7M
Top Position Liquidated / Trimmed
VRNA
前期市值: $91.2M
In Q3 2025, Caligan Partners LP made 21 total portfolio adjustments, initiating 7 new buys, adding to 7 positions, trimming 1 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.